Building communication to enable
robust manufacturing processes
The Advanced therapy medicinal products Manufacturing Community
Meet the people behind the community
Dr Lucy Foley Exmoor Pharma
Lucy is the CTO at eXmoor Pharma Concepts
Prior to joining the eXmoor Lucy was Lead Biopharmaceutical Engineer at the National Biologics Manufacturing Centre and a lecturer in Biopharmaceutical Engineering in the Department of Chemical Engineering and Advanced Materials at Newcastle University. Previously Lucy was a Research Associate in Newcastle University Business School where she worked with Profs Lyddiatt and Whitaker to understand the route to widespread adoption and process industrialisation of advanced therapies. Lucy holds visiting posts at Monash University, Melbourne and Newcastle University.
Prof Michael Whitaker Newcastle University
Michael is Professor of Physiology and co-Director of the joint Durham/Newcastle/NHS North East England Stem Cell Institute.
He is a Director of The Advanced Therapy Medicinal Products (ATMP) Manufacturing Community Limited and chairs the company board.
Michael is a Trustee of the Marine Biological Association of the United Kingdom and sits on the boards of several companies in the biosciences and energy sectors, including the Cell Therapy Catapult.
Dr Michael Delahaye Director of Cell Therapy Bioprocessing, BioPharmaceuticals R&D Cell Therapy Department, AstraZeneca
Michael has recently joined the BioPharmaceuticals R&D Cell Therapy Department at AstraZeneca, and brings with him almost 15 years of industrial experience within the cell and gene therapy sector. His key focus is the development and delivery of robust manufacturing processes, supported by rapid, high resolution characterisation tools to facilitate the production of cell therapies.
Previously, Michael held the position of Head of the Viral Vector Industrialisation team at the Cell and Gene Therapy Catapult. He’s led teams of experienced scientists within the Viral Gene Delivery program, responsible for managing the developmental output of the group within collaborative, commercial and supporting R&D operations. Prior to that, he held roles at TAP Biosystems (now part of Sartorius Stedim) and completed his EngD in 2011 following industrial collaboration with both OnyVax Ltd and ReNeuron Plc.
Abby Clark CPI
Abby is a Degree Level Apprentice Scientist working within the Downstream Processing team at the National Biologics Manufacturing Centre.
She joined CPI in 2019 primarily focusing on continuous processing through the use of automated systems whilst carrying out her degree in Biotechnology.
Abby has experience with complex protein purification as well as mRNA vaccine development.
Jef Pinxteren PhD Meatable
Jef joined the cellular meat company Meatable (Delft, The Netherlands) in December 2021.
Before that he worked as the Head of Process Development at Catalent Cell & Gene Therapy, at the Belgian site in Gosselies. He brings with him 15 years of R&D experience within the cell and gene therapy sector.
Before Catalent, Jef was leading the Operations and Process Development at Promethera Biosciences and before that he was leading the R&D activities of Athersys at the business unit in Europe (ReGenesys) and functioning as the unit manager.
Before that he worked in academia until late 2006, at University College London, UAB, the University of Gent and the Flemish Institute of Biotechnology (VIB), building knowledge in stem cell biology, immunology and proteomics.
Chris Mason AvroBio Inc.
Chris Mason is a co-founder and Chief Scientific Officer at AvroBio Inc., an ex vivo gene therapy company based in Cambridge, Massachusetts. Since 2008, he has been Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies.
He has a multidisciplinary track record, spanning R&D, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business.
Dr Stephen Ward Cell Therapy Catapult
Stephen was appointed Chief Operating Officer of the Cell Therapy Catapult in January 2013. He brings over 20 years of biological medicine research, development, and manufacturing experience to the organisation.
Stephen enjoys bringing cutting edge technologies to patients, by developing commercially viable products and has developed and validated scaleable, commercial manufacturing processes for cell based medicinal products, vaccines, and recombinant biologicals using Quality by Design principles.
Mark Lowdell Royal Free Hospital London
Professor Mark Lowdell PhD FRCPath FRSB is the Professor of Cell & Tissue Therapy at University College London and Director of the Centre for Cell, Gene & Tissue Therapeutics / Honorary Consultant Immunologist at Royal Free Hospital London.
He is a qualified diagnostic immunopathologist as well as holding MHRA Qualified Person status for the release of ATMPs for clinical trials and is the current Vice President (Europe & Middle East) of the International Society for Cell Therapy.
Paul Kemp HairClone
Paul is co-founder and Chief Executive Office of HairClone, a cell therapy company developing treatments for androgenic alopecia.
He has built a successful track record in all aspects of the business, from carrying out translational research, in-licensing technologies from Universities and out-licensing products to a variety of HealthCare Companies, designing, obtaining regulatory approval and running clinical trials in the US, Canada, UK and Europe.
Whilst the UK is excellent in scientific development of cell therapies, robust manufacturing processes, essential to establishing industry, now need to be developed.
Developing best practice in cell therapy manufacturing
By building a critical mass we can share best practice and act as a voice to suppliers, regulators and industry to establish robust cell therapy manufacture.
We are always looking for new members of the team. If you are interested please get in touch. email@example.com
If you think you would like to help us with the running of the amc community we would love to hear from you.